Nature Biotechnology 2006 Cormac Sheridan - Abstracts
| Nature Biotechnology 2006 Cormac Sheridan | |||||
| Title | Subject | Authors | |||
|---|---|---|---|---|---|
| Antibiotics au naturel. | Business | Cormac Sheridan | |||
| BioXell: An Italian Biotech success story? | Business | Cormac Sheridan | |||
| Diversa restructures, raining question over bioprospecting. | Business | Cormac Sheridan | |||
| European pharma consolidation generates quality spinoffs. | Business | Cormac Sheridan | |||
| Genentech raises stakes on PARP inhibitors.(poly (ADP-Ribose) polymerase) | Business | Cormac Sheridan | |||
| Interest heats up in gastrointestinal space.(anti-inflammatory biologics poised to become a multibillion-dollar revenue opportunity) | Business | Cormac Sheridan | |||
| Rising biotech appetite in the east.(MerLion Pharmaceuticals Private Ltd.) | Business | Cormac Sheridan | |||
| Serono changes tack.(Serono AG) | Business | Cormac Sheridan | |||
| Stem cell controversy to stall European tissue and cell therapy rules. | Business | Cormac Sheridan | |||
| TeGenero fiasco prompts regulatory rethink. | Business | Cormac Sheridan | |||
| Tysabri back on market. | Business | Cormac Sheridan | |||
This website is not affiliated with document authors or copyright owners. This page is provided for informational purposes only. Unintentional errors are possible.